{"id":"pre-stroke-antihypertensives","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Worsening stroke outcome from excessive BP reduction"},{"rate":null,"effect":"Renal dysfunction"}]},"_chembl":{"chemblId":"CHEMBL4208783","moleculeType":"Small molecule","molecularWeight":"590.67"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"These agents work by reducing systemic blood pressure in the acute stroke window, which may help limit cerebral edema, prevent hemorrhagic transformation, and reduce infarct expansion. The mechanism leverages the principle that controlled blood pressure reduction in the hyperacute phase can improve stroke outcomes, though the exact molecular targets depend on the specific agent used within this class.","oneSentence":"Pre-stroke antihypertensives are blood pressure-lowering agents designed to be administered acutely before or immediately after a stroke event to reduce neurological damage.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:29:49.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke with elevated blood pressure"},{"name":"Acute hemorrhagic stroke with hypertension"}]},"trialDetails":[{"nctId":"NCT05911568","phase":"","title":"Treatment With Endovascular Intervention for STroke Patients With Existing Disability","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2023-11-16","conditions":"Stroke, Stroke, Acute, Stroke, Ischemic","enrollment":1060},{"nctId":"NCT07002476","phase":"PHASE3","title":"Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion","status":"RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2025-06-19","conditions":"Stroke","enrollment":652},{"nctId":"NCT07279259","phase":"PHASE2","title":"Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management","status":"RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2026-01-15","conditions":"Stroke, Acute Ischemic Stroke, Thrombolysis","enrollment":340},{"nctId":"NCT05963568","phase":"PHASE3","title":"Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)","status":"NOT_YET_RECRUITING","sponsor":"Northern California Institute of Research and Education","startDate":"2026-01-01","conditions":"Stroke, Medication Adherence","enrollment":680},{"nctId":"NCT03710902","phase":"NA","title":"Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke","status":"RECRUITING","sponsor":"Jukka Putaala","startDate":"2018-10-17","conditions":"Ischemic Stroke, Transient Ischemic Attack, Atrial Fibrillation","enrollment":405},{"nctId":"NCT04054648","phase":"NA","title":"BedMed-Frail: Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations?","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2020-05-25","conditions":"Hypertension, Dementia","enrollment":776},{"nctId":"NCT04646902","phase":"","title":"Kynurenine/Tryptophan Ratio in Hypertension Associated to Obstructive Sleep Apnea","status":"UNKNOWN","sponsor":"Universidade Nova de Lisboa","startDate":"2021-03-25","conditions":"Hypertension Secondary","enrollment":203},{"nctId":"NCT05169021","phase":"PHASE4","title":"Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-12-31","conditions":"Cerebral Small Vessel Diseases, Stroke","enrollment":15000},{"nctId":"NCT04995146","phase":"","title":"Implementing International Standards of Practice in A Low Resource Country by Blended Training Modules to Improve Stroke Care","status":"UNKNOWN","sponsor":"Foundation University Islamabad","startDate":"2021-01-01","conditions":"Stroke","enrollment":100},{"nctId":"NCT03712033","phase":"","title":"TEC4Home Stroke - Feasibility of Home Telemonitoring Technology in Managing Hypertension Among Stroke/TIA Patients","status":"COMPLETED","sponsor":"Vancouver Coastal Health Research Institute","startDate":"2018-03-01","conditions":"Hypertension, Stroke, Blood Pressure, High","enrollment":50},{"nctId":"NCT01911494","phase":"NA","title":"Community Level Interventions for Pre-eclampsia","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2013-09","conditions":"Pre-eclampsia, Hypertension, Pregnancy Induced","enrollment":87500},{"nctId":"NCT01876667","phase":"NA","title":"An Evaluation of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients With Ischemic Stroke","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2010-07","conditions":"Stroke","enrollment":141},{"nctId":"NCT02947490","phase":"PHASE3","title":"Effectiveness of Self-monitoring and Treatment of Blood Pressure Following Stroke or Transient Ischaemic Attack","status":"COMPLETED","sponsor":"University of East Anglia","startDate":"2013-09","conditions":"Stroke","enrollment":165},{"nctId":"NCT00989716","phase":"PHASE3","title":"The Efficacy of Nitric Oxide in Stroke (ENOS) Trial","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2001-07","conditions":"Stroke","enrollment":3500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pre-stroke antihypertensives","genericName":"Pre-stroke antihypertensives","companyName":"University of Nottingham","companyId":"university-of-nottingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pre-stroke antihypertensives are blood pressure-lowering agents designed to be administered acutely before or immediately after a stroke event to reduce neurological damage. Used for Acute ischemic stroke with elevated blood pressure, Acute hemorrhagic stroke with hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}